The device was not returned for analysis.
A review of the lot history record identified no manufacturing nonconformities issued to the reported lot.
Based on the information reviewed, the cause for the reported hemorrhage could not be determined.
The reported patient effect of hemorrhage is listed in the mitraclip system instructions for use (ifu) are known possible complications associated with mitraclip procedures.
There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
This is filed to report that during the procedure, the steerable guide catheter (sgc) could have contributed to bleeding in the femoral artery requiring artery repair.
It was reported that this was a mitraclip procedure to treat degenerative mitral regurgitation (mr) with a grade of 4 with a prolapse.
The steerable guiding catheter was inserted and advanced without issue.
The clip delivery system (cds) was advanced to the mitral valve and grasping was attempted without issue; however, the patient started bleeding out and the abdomen became enlarged.
The clip was deployed without leaflet insertion due to the bleeding emergency.
After deployment, it was confirmed that the clip was inserted well in both leaflets and was stable; however, the patient was continued bleeding and mr remained at 4 but better than the initial mr grade.
It was informed, that the patient had a stent placed 2 days before and was on a high dose of plavix of 600mg which contributed to the bleeding.
Blood transfusion was performed.
In the physician's opinion, the sgc could have put pressure on that femoral artery causing the bleed.
The patient continued to bleed post procedure and was sent to for artery repair.
No additional information was provided.
|